<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bonnie L Bermas, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter H Schur, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvin M Matsumoto, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 04, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3756984"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A number of antiinflammatory and immunosuppressive drugs have improved the treatment of rheumatoid arthritis (RA), spondyloarthritis (SpA), systemic lupus erythematosus (SLE), and other rheumatic disorders. These conditions often impact reproductive-aged individuals. Much of the available data on the effects of antiinflammatory and immunosuppressive drugs on reproductive function and pregnancy are based upon maternal exposures. Less attention has been paid to the impact of these drugs on male reproductive function, particularly spermatogenesis and risk of teratogenicity in offspring.</p><p>The reproductive impact of antiinflammatory and immunosuppressive drugs in men with rheumatic disease will be reviewed here, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Impact on spermatogenesis</p><p class="bulletIndent1"><span class="glyph">●</span>Risk of teratogenicity in offspring (from sperm deoxyribonucleic acid [DNA] damage or drug exposure during intercourse)</p><p class="bulletIndent1"><span class="glyph">●</span>Guidance for the discontinuation of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> when planning pregnancy</p><p></p><p>The impact of these agents on female reproduction and the effects of specific cytotoxic agents on gonadal function in adult men are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a> and  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p class="headingAnchor" id="H3759728"><span class="h1">EFFECTS ON MALE GONADAL FUNCTION</span><span class="headingEndMark"> — </span>Infertility in men with rheumatic disorders can be due to disease activity and rarely to medication exposure [<a href="#rid1">1</a>]. Drug-induced infertility in men results from the toxic effects of the medication on the testes or the suppressive effects of the medications on the hypothalamic-pituitary-gonadal axis. The testes contain two anatomical units: the seminiferous tubules, composed of germ cells and Sertoli cells, and the interstitium, containing Leydig cells that produce testosterone. (See  <a class="medical medical_review" href="/z/d/html/7474.html" rel="external">"Male reproductive physiology"</a> and  <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">"Causes of male infertility"</a>.)</p><p>Spermatogenesis is much more likely to be disrupted than testosterone production because the actively proliferating germinal epithelium of the testes is more sensitive to damage (eg, from cytotoxic drugs) than are the Leydig cells. Sperm concentration, motility, and morphology are all surrogate markers that reflect fertility. The magnitude of the effect on sperm production is drug-specific and dose- and duration-dependent. Additional factors that may influence gonadal function in patients receiving these medications include effects of the underlying disease (eg, chronic kidney or pulmonary disease). (See  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a> and <a class="local">'Adverse effects on spermatogenesis'</a> below.)</p><p class="headingAnchor" id="H64692594"><span class="h2">Adverse effects on spermatogenesis</span><span class="headingEndMark"> — </span>Only two commonly used antirheumatic drugs, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> (SSZ), have been shown to adversely affect spermatogenesis. The antirheumatic agent with the most deleterious effect on male fertility is the alkylating agent (cyclophosphamide), which can induce irreversible or prolonged oligozoospermia or azoospermia, compromising fertility (see <a class="local">'Cyclophosphamide'</a> below). SSZ can cause reversible azoospermia or oligospermia and adversely impact sperm quality. (See <a class="local">'Sulfasalazine'</a> below.)</p><p>It is likely that the number of men with rheumatic diseases affected by drug-induced infertility has declined over time as <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> use for severe and organ-threatening manifestations of systemic lupus erythematosus (SLE), systemic vasculitis, and several other conditions has increasingly been replaced with other agents including <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. Similarly, the use of SSZ for conditions such as rheumatoid arthritis (RA) and spondyloarthritis (SpA) has become less common with the availability of similarly or more effective and well-tolerated biologic agents. (See <a class="local">'Cyclophosphamide'</a> below and  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a> and <a class="local">'Sulfasalazine'</a> below.)</p><p>When <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> is being administered to men, patients should be referred for cryopreservation of semen containing viable sperm for subsequent use in assisted reproductive technologies (ART) such as in vitro fertilization. (See <a class="local">'Preservation of fertility'</a> below and  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p>Limited data do not suggest that other antirheumatic drugs impact spermatogenesis. (See <a class="local">'Generally presumed safe'</a> below and <a class="local">'Limited data'</a> below.)</p><p class="headingAnchor" id="H3758895"><span class="h3">Cyclophosphamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a> is a cytotoxic alkylating agent, which can cause irreversible azoospermia that may induce permanent infertility. These effects are dose-related; cumulative cyclophosphamide doses of 6 to 10 grams are likely to result in oligospermia and often in irreversible azoospermia. Repeated exposure may be more harmful than single exposure at the same total dose.</p><p>Thus, male patients receiving doses in this range should be counseled about cryopreservation of sperm. (See <a class="local">'Preservation of fertility'</a> below and  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p>Detailed information regarding these and other adverse effects, use, and monitoring of this medication is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men", section on 'Chemotherapeutic agents associated with infertility'</a> and  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H3757628"><span class="h3">Sulfasalazine</span><span class="headingEndMark"> — </span>SSZ has been used since its development in the 1940s as an agent for the treatment of RA and inflammatory bowel disease (IBD). Specific details regarding the use and monitoring of this medication are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7524.html" rel="external">"Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"</a>.)</p><p>SSZ, which possesses both antiinflammatory properties mediated by its 5-aminosalicylic acid moiety and antibacterial characteristics associated with its sulfapyridine moiety, has been associated with reversible azoospermia or oligospermia in some men, along with reduced sperm motility and an increased proportion of abnormal forms. However, we do not routinely discontinue SSZ in men who are pursuing fertility. In men taking SSZ in whom attempts at pregnancy have not been successful, we obtain a semen analysis, and if abnormal, we suggest stopping the medication for three months to allow for recovery of spermatogenesis [<a href="#rid2">2-4</a>].</p><p class="headingAnchor" id="H4214588157"><span class="h2">No known impact on spermatogenesis</span><span class="headingEndMark"> — </span>Small cohorts, case series, and case reports of men receiving a range of medications for the treatment of rheumatic disease have not demonstrated any negative impact on their fertility [<a href="#rid5">5,6</a>].</p><p class="headingAnchor" id="H1366491423"><span class="h3">Generally presumed safe</span><span class="headingEndMark"> — </span>Several drugs do not appear to have a negative impact on gonadal function:</p><p class="bulletIndent1"><span class="glyph">●</span>TNF inhibitors – Although data are limited, paternal exposure to tumor necrosis factor (TNF) inhibitors does not appear to have a negative impact on spermatogenesis. Two early case series suggested that TNF inhibitors may impact sperm production and motility [<a href="#rid7">7,8</a>], but subsequent larger studies suggest that TNF inhibitors do not impair sperm production or function [<a href="#rid9">9-12</a>]. Studies have included patients receiving <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, and <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>; there are no data for <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a> or <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>. In a prospective study of 20 patients with active ankylosing spondylitis who were initially tested before starting TNF inhibitors, there were no adverse effects on sperm concentration or quality (motility and morphology) after 3 to 6 months of therapy, or after 12 months in the 6 patients retested [<a href="#rid12">12</a>]. In another study of semen samples from a cohort of 26 patients with SpA, abnormalities in sperm, including poor motility, were more pronounced in patients with active SpA who were not receiving TNF inhibitors than in TNF inhibitor-treated patients and in healthy men [<a href="#rid9">9</a>]. Sperm concentration and morphology did not differ between treated and non-treated groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> – Monotherapy with azathioprine (AZA) does not appear to reduce male fertility. In a study of 18 men treated with AZA (1.5 to 2 mg/kg/day) for at least three months for IBD, semen analyses were normal before and after 11 to 49 months of treatment [<a href="#rid13">13</a>]. AZA and its metabolite, <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a>, have been widely used in organ transplantation and for IBD, in addition to their uses in patients with rheumatic disease. (See  <a class="medical medical_review" href="/z/d/html/4083.html" rel="external">"Fertility, pregnancy, and nursing in inflammatory bowel disease", section on 'Azathioprine and mercaptopurine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> – No reduction in fertility of men taking methotrexate (MTX) in doses used to treat rheumatic diseases (up to 30 mg once per week) has been observed [<a href="#rid5">5,6,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NSAIDs, including <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> – The effects of nonsteroidal antiinflammatory drugs (NSAIDs) and salicylates have been evaluated in a number of studies [<a href="#rid5">5,12,15-18</a>]. While aspirin in doses greater than 2.6 grams a day can impede spermatogenesis, lower doses do not. In one case series of men exposed to greater than one nonsteroidal tablet a day, lower sperm counts were reported; however, these results are confounded by the fact that these men were being evaluated at an infertility clinic. Subsequent case series have not shown this effect.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil – MMF is an inhibitor of purine biosynthesis for which there have been no reports of impaired spermatogenesis [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> – Cyclosporine is a calcineurin inhibitor for which there have been no reports of impaired spermatogenesis [<a href="#rid20">20</a>].</p><p></p><p>Additional commonly used medications whose reproductive impact has not been studied include <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> and intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG); however, male infertility has not been reported with these agents despite their multiple decades of availability and use.</p><p class="headingAnchor" id="H1735895206"><span class="h3">Limited data</span><span class="headingEndMark"> — </span>There is insufficient evidence and reported experience related to the effects of the following biologic agents and targeted synthetic disease-modifying antirheumatic drugs (DMARDs; ie, Janus kinase [JAK] inhibitors) on male gonadal function, but the sum of available data regarding targeted biologic agents such as antibodies suggests they do not have adverse effects on fertility.</p><p class="bulletIndent1"><span class="glyph">●</span>Certolizumab</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">Golimumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">Abatacept</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">Tocilizumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="113315" href="/z/d/drug information/113315.html" rel="external">Sarilumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">Anakinra</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">Canakinumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">Ixekizumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">Belimumab</a></p><p></p><p>The effects of JAK inhibitors (<a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a>, peficitinib) and <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> on fertility are unknown.</p><p class="headingAnchor" id="H3757945"><span class="h1">TERATOGENICITY</span><span class="headingEndMark"> — </span>Male factor teratogenicity can occur by a direct drug effect on sperm development or with seminal fluid exposure during intercourse. However, limited data in men suggest that paternal use of antirheumatic drugs other than <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and potentially <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> do not cause congenital anomalies, unlike the greater potential for teratogenic effects of some of these agents in pregnant women (see  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>). Moreover, the risk of withdrawing therapy may be substantial. Therefore, in patients with active disease, the author suggests that male patients remain on their medications, with the exception of cyclophosphamide and thalidomide, while attempting conception. (See <a class="local">'Drugs to avoid'</a> below and <a class="local">'Generally presumed safe'</a> below.)</p><p class="headingAnchor" id="H1693338703"><span class="h2">Drugs to avoid</span><span class="headingEndMark"> — </span>Two medications, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, which are sometimes used in rheumatic disease patients, should not be used by the male partner when a couple is pursuing pregnancy, because of their known teratogenic risks. (See <a class="local">'Cyclophosphamide'</a> below and <a class="local">'Thalidomide'</a> below.)</p><p class="headingAnchor" id="H4185225195"><span class="h3">Cyclophosphamide</span><span class="headingEndMark"> — </span>There are limited data on the risk of teratogenicity in offspring of men with rheumatologic disorders (eg, systemic lupus erythematosus [SLE] and systemic vasculitis) treated with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, in part due to the drug's adverse impact on spermatogenesis. [<a href="#rid6">6</a>]. An increased risk of congenital anomalies in their offspring has not yet been demonstrated [<a href="#rid6">6</a>]. However, there is concern for potential teratogenicity as cyclophosphamide use in men with cancer results in significant sperm DNA damage [<a href="#rid21">21</a>]. In animals, exposure to cyclophosphamide also induces genetic damage [<a href="#rid22">22-24</a>].</p><p>In view of the indirect data from male animal models and men with cancer that demonstrate sperm DNA damage with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> use, we suggest that men should discontinue this medication for at least three months to allow for a full cycle of spermatogenesis before attempting conception. Our approach is consistent with published guidelines [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H1071547512"><span class="h3">Thalidomide</span><span class="headingEndMark"> — </span>There are no data on paternal exposure to <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> in men with rheumatic diseases; it is used rarely for these conditions, but has been employed in patients with refractory cutaneous lupus and cutaneous sarcoid, mucocutaneous manifestations of Behçet syndrome, and to an even more limited extent in several forms of inflammatory arthritis [<a href="#rid26">26-28</a>]<em>.</em> Nonetheless, given the high rate of teratogenicity after maternal exposure [<a href="#rid29">29</a>] and the presence of drug in the semen of men who have been treated with this agent [<a href="#rid30">30</a>], we recommend discontinuing thalidomide for four weeks prior to attempting conception. Some experts recommend the use of barrier contraception in men who are taking this agent [<a href="#rid30">30,31</a>]. The manufacturer and US Food and Drug Administration (FDA) recommend that males taking thalidomide (even those vasectomized) must use a latex or synthetic condom during any sexual contact with females of childbearing potential and for up to 28 days following discontinuation of therapy; and that males taking thalidomide must not donate sperm [<a href="#rid32">32</a>]. Some clinicians suggest continued condom use for 12 weeks after thalidomide is discontinued to allow for a full cycle of spermatogenesis.</p><p class="headingAnchor" id="H1971325127"><span class="h2">Generally presumed safe</span><span class="headingEndMark"> — </span>Paternal use of most antirheumatic drugs is generally considered to be safe (eg, without demonstrated evidence of risk to the fetus that exceeds the 3 to 5 percent risk of congenital anomalies observed in the general population), although data are generally limited [<a href="#rid5">5,6</a>]. Paternal use of these agents is also generally consistent with available expert guidelines that indicate that paternal exposure to these medications is compatible with pregnancy [<a href="#rid25">25,33,34</a>]. The agents in this category include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> – Paternal exposure to methotrexate (MTX) around the time of conception does not appear to have adverse consequences for pregnancy outcomes. In a prospective cohort of 113 pregnancies in which there was paternal exposure to low-dose MTX (up to 30 mg once weekly) around the time of conception, there was no increase in the rate of major congenital anomalies or spontaneous abortion with 412 nonexposed control pregnancies [<a href="#rid35">35</a>]; neither gestational age at delivery nor birth weights differed between groups. These findings are consistent with other smaller series [<a href="#rid36">36,37</a>]. However, a National Birth Registry reported two cases of orofacial defects among 50 pregnancies associated with paternal exposure to MTX (in the three months prior to conception) [<a href="#rid38">38</a>]. In another study, which included 49 fathers taking MTX for inflammatory arthritis at the time of conception, no increase in the risk of congenital anomalies was identified in the offspring [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a><strong> mofetil</strong> – Mycophenolate mofetil (MMF), an inhibitor of purine biosynthesis, does not appear to have an adverse effect on spermatogenesis or on fertility. In a study of 350 pregnancies fathered by 230 men, in which 155 were treated with MMF, there was no increase in the rate of major congenital anomalies [<a href="#rid19">19</a>]. These findings, observed in men who received solid organ transplants, have been supported by those of other studies that were also performed in transplantation patients [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">Leflunomide</a> – Leflunomide (LEF) is an antimetabolite that inhibits dihydroorotate dehydrogenase, the enzyme that catalyzes the rate-limiting step in pyrimidine biosynthesis [<a href="#rid42">42-47</a>]. We are unaware of studies that have directly examined its safety with respect to male gonadal function. Likewise, other than one report of a healthy baby born whose father was on LEF during conception, there are no available data on male-mediated fetal toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents have also been widely used without evidence raising concerns about teratogenicity:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> (SSZ)</p><p class="bulletIndent2"><span class="glyph">•</span>Glucocorticoids</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> (AZA)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a></p><p class="bulletIndent2"><span class="glyph">•</span>Tumor necrosis factor (TNF) inhibitors (other than <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">Abatacept</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a></p><p></p><p class="bulletIndent1">Limited data on glucocorticoids suggest that these medications do not increase the risk of teratogenicity. In a large cohort study from Denmark, there were 2380 paternal exposures of glucocorticoids in the three months before conception and no increased risk of congenital anomalies, preterm birth, or small-for-gestational-age infants was observed [<a href="#rid48">48</a>].</p><p></p><p class="headingAnchor" id="H3606745078"><span class="h2">Limited evidence</span><span class="headingEndMark"> — </span>There is a paucity of information regarding the safety of a number of agents, with systematic reviews [<a href="#rid6">6,12</a>], 2016 guidelines from the United Kingdom [<a href="#rid25">25</a>], and the 2020 guidelines from the American College of Rheumatology [<a href="#rid34">34</a>] suggesting that <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, and the monoclonal antibodies below are unlikely to be harmful:</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">Golimumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">Tocilizumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="113315" href="/z/d/drug information/113315.html" rel="external">Sarilumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">Anakinra</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">Canakinumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">Belimumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">Ixekizumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">Apremilast</a></p><p></p><p>Information regarding potential teratogenicity of the Janus kinase (JAK) inhibitors (<a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a>, peficitinib) is unavailable.</p><p class="headingAnchor" id="H3662248514"><span class="h1">MANAGEMENT OF MEN STARTING THERAPY</span></p><p class="headingAnchor" id="H3706656102"><span class="h2">Preservation of fertility</span><span class="headingEndMark"> — </span>A number of strategies have been explored to preserve fertility in men receiving cytotoxic medications, including semen cryopreservation, which is well-established as an effective approach, and the use of gonadotropin-releasing hormone (GnRH) agonists to suppress the pituitary-gonadal axis, which has not shown benefit in human studies [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H2888447178"><span class="h3">Cryopreservation of sperm</span><span class="headingEndMark"> — </span>We recommend cryopreservation of sperm in all men who plan to start treatment with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, the one drug with the potential to cause permanent azoospermia. However, this approach has some limitations. Among men who are starting cytotoxic chemotherapy, only 50 percent are offered sperm banking, in spite of guidelines that recommend that all men should be offered this service. Moreover, many insurance companies will not cover the monthly cost of maintaining the specimen. (See  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p class="headingAnchor" id="H902027645"><span class="h3">Hormonal suppression</span><span class="headingEndMark"> — </span>Studies using GnRH agonists to reversibly suppress the hypothalamic-pituitary-testicular axis have demonstrated no definitive benefit either in preserving spermatogenesis or in accelerating its recovery. We suggest not using this approach. (See  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p class="headingAnchor" id="H3939460703"><span class="h2">Assisted reproductive technologies (ART)</span><span class="headingEndMark"> — </span>With the advent of in vitro fertilization with intracytoplasmic sperm injection (ICSI), viable pregnancies occur with sperm concentrations that are much lower than normal. Even men with azoospermia should be evaluated to see if there are spermatozoa that could be extracted directly from the testis for ICSI. ART can be pursued for many drugs (with the exception of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>) while the patient is on or off therapy. (See  <a class="medical medical_review" href="/z/d/html/3261.html" rel="external">"Intracytoplasmic sperm injection"</a> and  <a class="medical medical_review" href="/z/d/html/7452.html" rel="external">"Treatments for male infertility", section on 'Retrieval of sperm'</a>.)</p><p class="headingAnchor" id="H2036151515"><span class="h2">Sulfasalazine-related infertility</span><span class="headingEndMark"> — </span>Men may continue <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> (SSZ) while pursuing pregnancy. In men taking SSZ in whom attempts at pregnancy have not been successful, we obtain a semen analysis, and if abnormal, we suggest stopping the medication for three months to allow for recovery of spermatogenesis. (See <a class="local">'Sulfasalazine'</a> above.)</p><p class="headingAnchor" id="H3733630566"><span class="h2">Avoid teratogenicity</span><span class="headingEndMark"> — </span>As noted above, the two drugs with potential teratogenicity are <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>. The approach to avoiding harmful fetal effects in men receiving either drug while pursuing fertility include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a> – We suggest, consistent with expert guidelines [<a href="#rid25">25</a>], that men discontinue this medication for at least three months to allow for a full cycle of spermatogenesis before attempting conception. (See <a class="local">'Cyclophosphamide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a> – Given the high rate of teratogenicity after maternal exposure to thalidomide and the presence of the drug in the semen of men who have been treated with the drug, we recommend discontinuing thalidomide for four weeks prior to attempting conception. Available guidelines suggest that after stopping the drug, men must use a latex or synthetic condom during any sexual contact with women of childbearing potential for up to four weeks; and they must not donate sperm [<a href="#rid32">32</a>]. Some clinicians suggest continued condom use for 12 weeks after thalidomide is discontinued to allow for a full cycle of spermatogenesis. (See <a class="local">'Thalidomide'</a> above.)</p><p></p><p class="headingAnchor" id="H398708459"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120032.html" rel="external">"Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs"</a>.)</p><p class="headingAnchor" id="H1186055"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15425.html" rel="external">"Patient education: Male infertility (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2180.html" rel="external">"Patient education: Treatment of male infertility (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3759533"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients considering use of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> should be advised regarding strategies for preservation of fertility. We suggest that all men who plan to undergo therapy with cyclophosphamide be counseled about obtaining a semen sample for cryopreservation prior to initiating therapy. The use of gonadotropin-releasing hormone (GnRH) agonists during cyclophosphamide treatment has not been shown either to preserve spermatogenesis or to accelerate its recovery. (See <a class="local">'Preservation of fertility'</a> above and  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a relative paucity of data regarding the effects on male gonadal function of most antiinflammatory and immunosuppressive drugs used in the treatment of rheumatic diseases. We suggest that <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> be discontinued for a minimum of three months before attempting pregnancy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Cyclophosphamide, an alkylating agent, is associated with a high risk of irreversible azoospermia and should therefore be used with caution in patients anticipating future attempts at pregnancy. (See <a class="local">'Cyclophosphamide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> (SSZ) can reversibly induce oligospermia or azoospermia, as well as abnormal sperm function. In men taking SSZ in whom attempts at pregnancy have not been successful, we obtain a semen analysis, and if abnormal, we suggest stopping the medication for three months to allow for recovery of spermatogenesis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Sulfasalazine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a> is used rarely for rheumatic diseases; it is highly teratogenic after maternal exposure and the drug is present in the semen of men being treated with this agent. We recommend discontinuing thalidomide for four weeks prior to attempting conception (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). Some experts and regulators recommend the use of barrier contraception (ie, a latex or synthetic condom) in men who are taking this agent, including those vasectomized, and for up to 28 days following discontinuation of therapy. Some clinicians also suggest continued condom use for 12 weeks after thalidomide is discontinued to allow for a full cycle of spermatogenesis. (See <a class="local">'Thalidomide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paternal exposure to several drugs, including <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF), <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> (LEF), <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (AZA), and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, has not been associated with adverse effects on male gonadal function or increased fetal risk. <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> and intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) are widely used and are not known to have adverse effects on male gonadal function. (See <a class="local">'No known impact on spermatogenesis'</a> above and <a class="local">'Generally presumed safe'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The impact of most biologic agents on male gonadal function is unknown, but targeted biologic agents such as antibodies are not known to have adverse effects on fertility or to result in adverse pregnancy outcomes. These medications include tumor necrosis factor (TNF) inhibitors, <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, and <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>. The effects of the Janus kinase (JAK) inhibitors on fertility and on the fetus are unknown. (See <a class="local">'Generally presumed safe'</a> above and <a class="local">'No known impact on spermatogenesis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tiseo BC, Cocuzza M, Bonfa E, et al. Male fertility potential alteration in rheumatic diseases: a systematic review. Int Braz J Urol 2016; 42:11.</a></li><li><a class="nounderline abstract_t">Birnie GG, McLeod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut 1981; 22:452.</a></li><li><a class="nounderline abstract_t">Toovey S, Hudson E, Hendry WF, Levi AJ. Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 1981; 22:445.</a></li><li><a class="nounderline abstract_t">O'Moráin C, Smethurst P, Doré CJ, Levi AJ. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984; 25:1078.</a></li><li><a class="nounderline abstract_t">Micu MC, Ostensen M, Villiger PM, et al. Paternal exposure to antirheumatic drugs-What physicians should know: Review of the literature. Semin Arthritis Rheum 2018; 48:343.</a></li><li><a class="nounderline abstract_t">Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Semin Arthritis Rheum 2019; 48:911.</a></li><li><a class="nounderline abstract_t">Montagna GL, Malesci D, Buono R, Valentini G. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents. Ann Rheum Dis 2005; 64:1667.</a></li><li><a class="nounderline abstract_t">Mahadevan U, Terdiman JP, Aron J, et al. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis 2005; 11:395.</a></li><li><a class="nounderline abstract_t">Villiger PM, Caliezi G, Cottin V, et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 2010; 69:1842.</a></li><li><a class="nounderline abstract_t">Paschou S, Voulgari PV, Vrabie IG, et al. Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol 2009; 36:351.</a></li><li><a class="nounderline abstract_t">Said TM, Agarwal A, Falcone T, et al. Infliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro model. Fertil Steril 2005; 83:1665.</a></li><li><a class="nounderline abstract_t">Micu MC, Micu R, Surd S, et al. TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. Rheumatology (Oxford) 2014; 53:1250.</a></li><li><a class="nounderline abstract_t">Dejaco C, Mittermaier C, Reinisch W, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2001; 121:1048.</a></li><li><a class="nounderline abstract_t">El-Beheiry A, El-Mansy E, Kamel N, Salama N. Methotrexate and fertility in men. Arch Androl 1979; 3:177.</a></li><li><a class="nounderline abstract_t">Martini AC, Molina RI, Tissera AD, et al. Analysis of semen from patients chronically treated with low or moderate doses of aspirin-like drugs. Fertil Steril 2003; 80:221.</a></li><li><a class="nounderline abstract_t">Porat-Soldin O, Soldin SJ. Preliminary studies on the in vitro and in vivo effect of salicylate on sperm motility. Ther Drug Monit 1992; 14:366.</a></li><li><a class="nounderline abstract_t">Ingram MJ, Zeller E, Moss GP, Hall CE. A potential anti-implantation and spermicidal strategy: putative derivatives of nonoxynol-9 and anti-inflammatory agents and their spermicidal activity. Eur J Contracept Reprod Health Care 2006; 11:258.</a></li><li><a class="nounderline abstract_t">Nukumizu LA, Gonçalves Saad C, Ostensen M, et al. Gonadal function in male patients with ankylosing spondylitis. Scand J Rheumatol 2012; 41:476.</a></li><li><a class="nounderline abstract_t">Jones A, Clary MJ, McDermott E, et al. Outcomes of pregnancies fathered by solid-organ transplant recipients exposed to mycophenolic acid products. Prog Transplant 2013; 23:153.</a></li><li><a class="nounderline abstract_t">Haberman J, Karwa G, Greenstein SM, et al. Male fertility in cyclosporine-treated renal transplant patients. J Urol 1991; 145:294.</a></li><li><a class="nounderline abstract_t">Choy JT, Brannigan RE. The determination of reproductive safety in men during and after cancer treatment. Fertil Steril 2013; 100:1187.</a></li><li><a class="nounderline abstract_t">Trasler JM, Hales BF, Robaire B. Chronic low dose cyclophosphamide treatment of adult male rats: effect on fertility, pregnancy outcome and progeny. Biol Reprod 1986; 34:275.</a></li><li><a class="nounderline abstract_t">Codrington AM, Hales BF, Robaire B. Spermiogenic germ cell phase-specific DNA damage following cyclophosphamide exposure. J Androl 2004; 25:354.</a></li><li><a class="nounderline abstract_t">Taylor JD, Baumgartner A, Schmid TE, Brinkworth MH. Responses to genotoxicity in mouse testicular germ cells and epididymal spermatozoa are affected by increased age. Toxicol Lett 2019; 310:1.</a></li><li><a class="nounderline abstract_t">Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016; 55:1693.</a></li><li><a class="nounderline abstract_t">Kumar P, Das A, Lal NR, et al. Safety of important dermatological drugs (retinoids, immune suppressants, anti androgens and thalidomide) in reproductively active males with respect to pregnancy outcome: A brief review of literature. Indian J Dermatol Venereol Leprol 2018; 84:539.</a></li><li><a class="nounderline abstract_t">Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363:1802.</a></li><li><a class="nounderline abstract_t">Fairley JL, Oon S, Saracino AM, Nikpour M. Management of cutaneous manifestations of lupus erythematosus: A systematic review. Semin Arthritis Rheum 2020; 50:95.</a></li><li><a class="nounderline abstract_t">Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 2015; 105:140.</a></li><li><a class="nounderline abstract_t">Teo SK, Harden JL, Burke AB, et al. Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos 2001; 29:1355.</a></li><li><a class="nounderline abstract_t">Zakhem GA, Motosko CC, Mu EW, Ho RS. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review. J Am Acad Dermatol 2019; 80:957.</a></li><li class="breakAll">Thalidomide highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf (Accessed on October 05, 2019).</li><li><a class="nounderline abstract_t">Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford) 2016; 55:1698.</a></li><li><a class="nounderline abstract_t">Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2020; 72:529.</a></li><li><a class="nounderline abstract_t">Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology (Oxford) 2014; 53:757.</a></li><li><a class="nounderline abstract_t">Lee CY, Jin C, Mata AM, et al. A pilot study of paternal drug exposure: the Motherisk experience. Reprod Toxicol 2010; 29:353.</a></li><li><a class="nounderline abstract_t">Beghin D, Cournot MP, Vauzelle C, Elefant E. Paternal exposure to methotrexate and pregnancy outcomes. J Rheumatol 2011; 38:628.</a></li><li><a class="nounderline abstract_t">Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012; 41:196.</a></li><li><a class="nounderline abstract_t">Wallenius M, Lie E, Daltveit AK, et al. No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs. Arthritis Rheumatol 2015; 67:296.</a></li><li><a class="nounderline abstract_t">Morken NH, Diaz-Garcia C, Reisaeter AV, et al. Obstetric and neonatal outcome of pregnancies fathered by males on immunosuppression after solid organ transplantation. Am J Transplant 2015; 15:1666.</a></li><li><a class="nounderline abstract_t">Midtvedt K, Bergan S, Reisæter AV, et al. Exposure to Mycophenolate and Fatherhood. Transplantation 2017; 101:e214.</a></li><li><a class="nounderline abstract_t">Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003; 30:241.</a></li><li><a class="nounderline abstract_t">Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001; 63:106.</a></li><li><a class="nounderline abstract_t">De Santis M, Straface G, Cavaliere A, et al. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis 2005; 64:1096.</a></li><li><a class="nounderline abstract_t">Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010; 62:1494.</a></li><li><a class="nounderline abstract_t">Weber-Schoendorfer C, Beck E, Tissen-Diabaté T, Schaefer C. Leflunomide - A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. Reprod Toxicol 2017; 71:101.</a></li><li><a class="nounderline abstract_t">Bérard A, Zhao JP, Shui I, Colilla S. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis 2018; 77:500.</a></li><li><a class="nounderline abstract_t">Larsen MD, Friedman S, Magnussen B, Nørgård BM. Birth Outcome of Children Fathered by Men Treated with Systemic Corticosteroids during the Conception Period - A Cohort Study based on Nationwide Data. Basic Clin Pharmacol Toxicol 2018; 122:133.</a></li><li><a class="nounderline abstract_t">Pendse S, Ginsburg E, Singh AK. Strategies for preservation of ovarian and testicular function after immunosuppression. Am J Kidney Dis 2004; 43:772.</a></li></ol></div><div id="topicVersionRevision">Topic 15904 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27120778" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Male fertility potential alteration in rheumatic diseases: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6114898" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence of sulphasalazine-induced male infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6114897" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sulphasalazine and male infertility: reversibility and possible mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6148293" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Reversible male infertility due to sulphasalazine: studies in man and rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29502800" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Paternal exposure to antirheumatic drugs-What physicians should know: Review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30220537" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227427" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15803031" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Infliximab and semen quality in men with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610443" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19040305" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15950634" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Infliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24599921" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : TNF-αinhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11677195" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Azathioprine treatment and male fertility in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/518200" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Methotrexate and fertility in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12849830" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Analysis of semen from patients chronically treated with low or moderate doses of aspirin-like drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1448842" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Preliminary studies on the in vitro and in vivo effect of salicylate on sperm motility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17484190" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A potential anti-implantation and spermicidal strategy: putative derivatives of nonoxynol-9 and anti-inflammatory agents and their spermicidal activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22827405" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Gonadal function in male patients with ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782663" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Outcomes of pregnancies fathered by solid-organ transplant recipients exposed to mycophenolic acid products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1988720" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Male fertility in cyclosporine-treated renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993923" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The determination of reproductive safety in men during and after cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3082378" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chronic low dose cyclophosphamide treatment of adult male rats: effect on fertility, pregnancy outcome and progeny.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15064312" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Spermiogenic germ cell phase-specific DNA damage following cyclophosphamide exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30980909" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Responses to genotoxicity in mouse testicular germ cells and epididymal spermatozoa are affected by increased age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26750124" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29998864" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Safety of important dermatological drugs (retinoids, immune suppressants, anti androgens and thalidomide) in reproductively active males with respect to pregnancy outcome: A brief review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172781" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31526594" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Management of cutaneous manifestations of lupus erythematosus: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26043938" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Thalidomide-induced teratogenesis: history and mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560881" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Thalidomide is distributed into human semen after oral dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30287313" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30287313" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26750125" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32090480" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24369411" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20096774" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A pilot study of paternal drug exposure: the Motherisk experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239747" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Paternal exposure to methotrexate and pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22401133" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25418443" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25868657" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Obstetric and neonatal outcome of pregnancies fathered by males on immunosuppression after solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28346297" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Exposure to Mycophenolate and Fatherhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12563675" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241434" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15958772" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20131283" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Birth outcomes in women who have taken leflunomide during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28478049" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Leflunomide - A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222350" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28804964" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Birth Outcome of Children Fathered by Men Treated with Systemic Corticosteroids during the Conception Period - A Cohort Study based on Nationwide Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15112167" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Strategies for preservation of ovarian and testicular function after immunosuppression.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
